ImmunoGen Initiates Phase II Clinical Trial of HuC242-DM4

ImmunoGen announced that it initiated a Phase II clinical study that evaluates its huC242-DM4 compound for the treatment of stomach (gastric) cancer.

According to ImmunoGen, this single-agent Phase II study is designed to assess the activity — as measured by objective responses — and tolerability of huC242-DM4 for the treatment of stomach cancer.

To qualify for enrollment, patients must have metastatic or locally-advanced gastric or gastroesophageal cancer and have failed front-line chemotherapy.

Patients receive 168 mg/m2 of huC242-DM4, administered once every three weeks, the company said. The trial is expected to include up to approximately 40 response-evaluable patients and will be conducted at multiple centers in the U.S., the company added.